Orchestra BioMed Holdings

OBIO

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Orchestra BioMed is a medical device and biotech company that develops treatments for serious heart and blood pressure conditions. Its main product is Virtue SAB, a drug-coated balloon designed to treat coronary artery disease — a condition where arteries in the heart get blocked. The company also works on BackBeat, a pacemaker-based therapy aimed at treating high blood pressure in patients who already need a pacemaker.

Orchestra BioMed makes money by partnering with larger medical device companies rather than selling products directly on its own. It has a partnership with Medtronic, one of the world's biggest medical device makers, to help develop and commercialize its technologies. The company is small, based in the United States, and is not yet profitable — spending far more than it earns, which is typical for early-stage biotech firms. The key risk is that its products must still pass regulatory reviews, and any delays or failures in clinical trials could significantly impact the company's future.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-89.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+24.0% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

31.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~17 months

$110M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Orchestra BioMed Holdings's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

71.6%

Premium pricing power — 71.6% gross margin

Profit after running costs

Operating Margin

-25404.5%

Losing money on operations — -25404.5%

Return on the money invested

ROCE

-116.3%

Weak — -116.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+986.1%

Fast-growing sales (+986.1% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-184.8%

Burning cash (-184.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.69

Moderate — manageable debt (0.69)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial